secwatch / observer
8-K filed September 21, 2022, 7:59 PM ET ticker GPGI CIK 0001823144
leadership confidence high sentiment neutral materiality 0.50

CompoSecure director Basile resigns; Paul Galant appointed to board effective Sept 21, 2022

GPGI, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Paul S. Galant

Director
GPGI · GPGI, Inc.
Effective
2022-09-21
Filed
September 21, 2022, 7:59 PM ET
On September 21, 2022, Roman designated Paul S. Galant to serve as a director on the Board and on September 21, 2022, the Board elected Mr. Galant to serve on the Board, effective immediately
Departed

Dr. Donald Basile

Director
GPGI · GPGI, Inc.
Effective
2022-09-21
Successor
Paul S. Galant
Filed
September 21, 2022, 7:59 PM ET
Dr. Donald Basile notified the Board of Directors (the “Board”) of CompoSecure, Inc. (the “Company”) that he had resigned from the Board, effective as of 8:59 A.M. ET on September 21, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul S. Galant was appointed as Director at GPGI, Inc..

Action
appointed
Role
Director
Exact text from the filing
On September 21, 2022, Roman designated Paul S. Galant to serve as a director on the Board and on September 21, 2022, the Board elected Mr. Galant to serve on the Board, effective immediately
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Donald Basile resigned as Director at GPGI, Inc..

Action
resigned
Role
Director
Exact text from the filing
Dr. Donald Basile notified the Board of Directors (the “Board”) of CompoSecure, Inc. (the “Company”) that he had resigned from the Board, effective as of 8:59 A.M. ET on September 21, 2022.
View on SEC.gov

GPGI, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-22-101927
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.